The Orphan Drugs Summit is back for the 6th edition and after 5 successful years in Copenhagen we are happy to announce that we are moving to Amsterdam!
What has not changed is that orphan drugs are highly challenging from discovery to postmarket surveillance and comprehensive review of adverse events. That is why we are continuing to create THE platform for payers, hospital representatives, patient organisations, venture capitalists, regulatory bodies, drug developers, researchers and industry associations to come together to overcome major challenges.
2016 is an important year as the global orphan drugs market is expected to reach a $176 billion mark in only 4 years from now. With a 10.5% compound annual growth rate, the prescription sales in the orphan sector is growing at twice the rate of the overall prescription market.
However, there are major factors like high initial investment, regulatory obstacles and clinical hurdles that constrain the run of the orphan drugs market. The regulatory framework and standards vary from country to country, making it difficult for companies to operate on a global level, especially in Europe.
If you are looking forward to being part of the orphan drugs business and policy of tomorrow, attend the Orphan Drugs Summit 2016.